Search This Blog

Wednesday, April 22, 2026

Amneal details $750M Kashiv BioSciences acquisition

 

Amneal beats Q1 2026 estimates with EPS $0.27 (+29% YoY), revenue $722.5M (+4% YoY), details $750M Kashiv BioSciences acquisition

  • Amneal to acquire Kashiv BioSciences for $375M cash, $375M equity plus up to $350M milestone and royalty payments
  • Company filed SEC report today disclosing Q1 2026 results and details of the $750M Kashiv acquisition
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)